Prostate and other male cancers:

Indications for: FIRMAGON

Advanced prostate cancer.

Adult Dosage:

Give by SC inj in abdomen once every 28 days; avoid waist and rib areas. Two 120mg injections once, then one 80mg inj once every 28 days.

Children Dosage:

Not established.

FIRMAGON Warnings/Precautions:

Congenital long QT syndrome. CHF. Correct electrolyte abnormalities. Monitor electrolytes and ECG periodically. Monitor serum PSA. Discontinue if serious hypersensitivity reaction occurs; do not rechallenge. Moderate or severe renal impairment (CrCl <50mL/min). Severe hepatic impairment. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended.

FIRMAGON Classification:

GnRH antagonist.

FIRMAGON Interactions:

Caution with concomitant drugs known to prolong the QT interval.

Adverse Reactions:

Inj site reactions (eg, pain, erythema, swelling, induration), hot flashes, increased weight, fatigue, increased transaminases, increased gamma-glutamyltransferase; QT prolongation.

How Supplied:

Treatment Initiation pack (120mg/vial)—2 (w. supplies); Treatment Maintenance pack (80mg/vial)—1 (w. supplies)